Your browser doesn't support javascript.
loading
High Exposure to Perfluoroalkyl Substances and Antibody Responses to SARS-CoV-2 mRNA Vaccine-an Observational Study in Adults from Ronneby, Sweden.
Andersson, Axel G; Lundgren, Anna; Xu, Yiyi; Nielsen, Christel; Lindh, Christian H; Pineda, Daniela; Cederlund, Julia; Pataridou, Elisavet; Søgaard Tøttenborg, Sandra; Ugelvig Petersen, Kajsa; Fletcher, Tony; Lagging, Martin; Bemark, Mats; Jakobsson, Kristina; Li, Ying.
Afiliação
  • Andersson AG; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Lundgren A; Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Xu Y; Department of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Nielsen C; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Lindh CH; Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.
  • Pineda D; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Cederlund J; Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.
  • Pataridou E; Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.
  • Søgaard Tøttenborg S; Region Blekinge, Karlskrona, Sweden.
  • Ugelvig Petersen K; Region Blekinge, Karlskrona, Sweden.
  • Fletcher T; Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Lagging M; Department of Occupational and Environmental Medicine, Copenhagen University Hospital -Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Bemark M; Department of Occupational and Environmental Medicine, Copenhagen University Hospital -Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Jakobsson K; Department of Public Health, Environments & Society, London School of Hygiene & Tropical Medicine, London, UK.
  • Li Y; Department of Infectious Diseases, Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Environ Health Perspect ; 131(8): 87007, 2023 08.
Article em En | MEDLINE | ID: mdl-37578904
ABSTRACT

BACKGROUND:

Per- and polyfluoroalkyl substances (PFAS) are widely used, environmentally ubiquitous, and stable chemicals that have been associated with lower vaccine-induced antibody responses in children; however, data on adults are limited. The drinking water from one of the two waterworks in Ronneby, Sweden, was heavily contaminated for decades with PFAS from firefighting foams, primarily perfluorohexane sulfonic acid and perfluorooctanesulfonic acid (PFOS). Vaccination against SARS-CoV-2 offered a unique opportunity to investigate antibody responses to primary vaccination in adults who had been exposed to PFAS.

OBJECTIVES:

Our objective was to evaluate associations between PFAS, across a wide range of exposure levels, and antibody responses in adults 5 wk and 6 months after a two-dose vaccination regime against SARS-CoV-2.

METHODS:

Adults age 20-60 y from Ronneby (n=309, median PFOS serum level 47 ng/mL, fifth to 95th percentile 4-213 ng/mL) and a group with background exposure (n=47, median PFOS serum level 4 ng/mL) received two doses of the Spikevax (Moderna) mRNA vaccine. The levels of seven PFAS were measured in serum before vaccination. Serum immunoglobulin G antibodies against the SARS-CoV-2 spike antigen (S-Abs) were measured before vaccination and at 5 wk (n=350) and 6 months (n=329) after the second vaccine dose. Linear regression analyses were fitted against current, historical, and prenatal exposure to PFAS, adjusting for sex, age, and smoking, excluding individuals with previous SARS-CoV-2-infection.

RESULTS:

PFAS exposure, regardless of how it was estimated, was not negatively associated with antibody levels 5 wk [current PFOS -0.5% S-Abs/PFOS interquartile range (IQR); 95% confidence interval (CI) -8, 7] or 6 months (current PFOS 3% S-Abs/PFOS IQR; 95% CI -6, 12) after COVID-19 vaccination.

DISCUSSION:

Following a strict study protocol, rigorous study design, and few dropouts, we found no indication that PFAS exposure negatively affected antibody responses to COVID-19 mRNA vaccination for up to 6 months after vaccination. https//doi.org/10.1289/EHP11847.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Ácidos Alcanossulfônicos / Fluorocarbonos / COVID-19 Tipo de estudo: Observational_studies Limite: Adult / Child / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Environ Health Perspect Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Ácidos Alcanossulfônicos / Fluorocarbonos / COVID-19 Tipo de estudo: Observational_studies Limite: Adult / Child / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Environ Health Perspect Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia